Últimas noticias sobre Envirotech Vehicles (NASDAQ:EVTV) Bolsa

Envirotech Vehicles

Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.

Envirotech Vehicles Inc

WIIM

Domino's Pizza shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Baird analyst Shrenik Kothari maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and raises the price target from $385 to $425.

News

Price Target

Analyst Ratings

PANW

Baird Maintains Outperform on Palo Alto Networks, Raises Price Target to $425

ULTA

Ulta Beauty shares are trading lower after Berkshire Hathaway cut its position in the stock.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and maintains $3 price target.

Reiteration

RNAZ

HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/66585980a3067c00012c48c0/david-roman">Goldman Sachs analyst David Roman </a>initiated coverage on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral rating and announced a price target of $108. HealthEquity shares closed at $95.70 on Thursday. <a href="https://www.benzinga.com/quote/HQY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $26.02 on Thursday. <a href="https://www.benzinga.com/quote/PFE/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/insights/analyst-ratings/24/10/41494343/analyst-expectations-for-mastecs-future">Stifel analyst Brian Brophy</a> initiated coverage on EMCOR Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy rating and announced a price target of $600. EMCOR shares closed at $498.11 on Thursday. <a href="https://www.benzinga.com/quote/EME/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Harry Read initiated coverage on Insight Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) with a Buy rating and announced a price target of $220. Insight Enterprises shares closed at $152.63 on Thursday. See how other analysts view this stock.</li>
<li>Wolfe Research analyst Alexandria Hammond initiated coverage on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with an Outperform rating and announced a price target of $190. Johnson &amp; Johnson shares closed at $151.87 on Thursday. <a href="https://www.benzinga.com/quote/JNJ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png" alt="" class="wp-image-650063" style="width:716px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15072028/image-169.png 1196w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

NSIT

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.13) by 92.31 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $5.36 million which beat the analyst consensus estimate of $2.69 million by 99.29 percent. This is a 2.42K percent increase over sales of $213.00 thousand the same period last year.

SLGL

Sol-Gel Technologies Q3 EPS $(0.01) Beats $(0.13) Estimate, Sales $5.36M Beat $2.69M Estimate

Baird analyst Wesley Golladay maintains Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) with a Neutral and raises the price target from $26 to $29.

Baird Maintains Neutral on Kite Realty Gr Trust, Raises Price Target to $29

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Baird analyst Jack Allen maintains MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Outperform and lowers the price target from $8 to $4.

INKT

Baird Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $4

Citigroup analyst Beatrice Lam downgrades Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) from Buy to Neutral and lowers the price target from $2.3 to $0.5.

Downgrades

Citigroup Downgrades Gogoro to Neutral, Lowers Price Target to $0.5

HC Wainwright &amp; Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and maintains $8 price target.

PSTV

HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target

Baird analyst Joel Beatty maintains Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) with a Outperform and raises the price target from $6 to $7.

IMMP

Baird Maintains Outperform on Immutep, Raises Price Target to $7

"The CHMP's positive opinion marks an important milestone for patients in Europe with non-epithelioid mesothelioma, who experience worse survival outcomes than patients with epithelioid mesothelioma," said Dr. Gregory Lubiniecki, vice president, oncology clinical research, Merck Research Laboratories. "The positive CHMP opinion moves us closer to offering a new first-line treatment option with a proven overall survival benefit for certain patients in the European Union with this difficult-to-treat cancer."

Merck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult  Patients With Unresectable Non-epithelioid Malignant Pleural Mesothelioma

Baird analyst Colleen Kusy maintains Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) with a Outperform and raises the price target from $32 to $40.

ELVN

Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgrades Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) from Buy to Neutral.

POAI

HC Wainwright & Co. Downgrades Predictive Oncology to Neutral

Baird analyst Brian Skorney maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and raises the price target from $294 to $300.

BIIB

Baird Maintains Outperform on Biogen, Raises Price Target to $300

PLTR: 4% &#x7C; <a href="https://www.benzinga.com//node/41992063">Palantir Technologies shares are trading higher after the company announced it will transfer its stock exchange listing over to the Nasdaq.</a>
&nbsp;
OKLO: -11% &#x7C; <a href="https://www.benzinga.com//node/41993934">Oklo shares are trading lower. The company reported Q3 financial results.</a>
&nbsp;
BENF: 146% &#x7C; <a href="https://www.benzinga.com//node/41993628">Beneficient shares are trading higher after the company reported a year-over-year increase in Q2 revenue results.</a>

Movers

BENF

OKLO

PLTR

Market-Moving News for November 15th

CANG

Cango Completed Previously Announced Acquisition Of On-rack Crypto Mining Machines With An Aggregate Hashrate Of 32 Exahash Per Second For $256M From Bitmain Technologies Georgia Limited And Bitmain Development Limited

Stifel analyst Brian Brophy initiates coverage on Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) with a Buy rating and announces Price Target of $108.

Stifel Initiates Coverage On Limbach Holdings with Buy Rating, Announces Price Target of $108

Stifel analyst Brian Brophy initiates coverage on Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) with a Buy rating and announces Price Target of $71.

Stifel Initiates Coverage On Everus Construction Group with Buy Rating, Announces Price Target of $71

EV Company News For The Month Of May 2024

EV Company News For The Month Of June 2024

EV Company News For The Month Of July 2024

EV Company News For The Month Of August 2024

EV Company News For The Month Of September 2024

Envirotech Vehicles ( ($EVTV) ) has provided an update. Envirotech Vehicles, an innovator in electric commercial vehicles, has appointed Jason Madd...

Envirotech Vehicles Appoints New Leadership Team

Envirotech acquires Maddox Industries

17:16 EDT Envirotech Vehicles (EVTV) files to sell 13.61M shares of common stock for holders Published first on TheFly – the ultimate source for re...

Envirotech Vehicles files to sell 13.61M shares of common stock for holders

EV Company News For The Month Of October 2024

Envirotech Vehicles ( ($EVTV) ) has issued an update. Envirotech Vehicles, Inc. has acquired Maddox Industries, a key player in government contract...

Envirotech Vehicles Expands with Maddox Industries Acquisition

AYRO

BAMXF

BATT

BCCMY

BLBD

BLNK

BMCLF

BMWYY

BYDDF

BYDDY

BYMOF

DNFGF

DNFGY

ELMSQ

ELMWQ

ENLAY

ESOCF

EVTV

FUJHF

FUJHY

GELYF

GELYY

GOEV

GOEVW

GOOG

GOOGL

GWLLF

GWLLY

HNDAF

HYLN

HYMTF

IDEX

KMTUF

KMTUY

KNDI

LAAOF

LCID

MAHMF

MBGAF

MBGYY

MMTOF

MZDAF

MZDAY

NIOIF

NKLA

NSANF

NSANY

POAHF

POAHY

PSNY

PSNYW

RACE

RIVN

RNLSY

RNSDF

STLA

SZKMF

SZKMY

TOYOF

TSLA

TSMWF

VFSWW

VLKAF

VLKPF

VWAGY

VWAPY

WKHS

XIACF

XIACY

XPEV

XPNGF

Press Releases

Envirotech Vehicles Announces an Update on $4.3 million Revenue Backlog Related to NJ ZIP Program

Envirotech Vehicles Announces Sales & Purchase Agreement

Envirotech Vehicles Announces Delivery of Electric Vehicles and Forklift to PlugD

Earnings

Envirotech Vehicles Announces First Quarter 2024 Financial Results

Management

Envirotech Vehicles Ramps Up Production Team

Envirotech Vehicles "Bumble Bee" Bus Update

Envirotech Vehicles Set for Major Expansion with $10 Million Financing Boost and $100 Million Commitment

EVTV Envirotech Welcomes Visionary Entrepreneur Brock Pierce to Board of Directors

EVTV Envirotech Adds Proven Leaders Jason Maddox and Elgin Tracy

Envirotech (NASDAQ: EVTV) Acquires Maddox Industries to Propel U.S. Manufacturing and Electric Vehicle Initiatives

Thunder Power Holdings, Inc. - Common Stock

Thunder Power Holdings

Cenntro

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

General Motors

Canoo

Honda Motor Co

Lucid Gr

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

Mullen Automotive

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

ZEEKR Intelligent Tech

ENVIROTECH VEHICLES INC by Envirotech Vehicles Inc.

Comments

Envirotech Vehicles

Noticias

Últimas noticias sobre Envirotech Vehicles (NASDAQ:EVTV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL